FIORILLO, LUCIA
 Distribuzione geografica
Continente #
NA - Nord America 108
EU - Europa 98
AS - Asia 75
SA - Sud America 31
AF - Africa 2
Totale 314
Nazione #
US - Stati Uniti d'America 101
IT - Italia 62
SG - Singapore 41
BR - Brasile 26
DE - Germania 13
CN - Cina 11
VN - Vietnam 9
FI - Finlandia 7
IN - India 7
CA - Canada 5
GB - Regno Unito 4
NL - Olanda 4
IQ - Iraq 3
RU - Federazione Russa 3
AR - Argentina 2
EE - Estonia 2
ZA - Sudafrica 2
BD - Bangladesh 1
BO - Bolivia 1
CH - Svizzera 1
CO - Colombia 1
CZ - Repubblica Ceca 1
ID - Indonesia 1
LB - Libano 1
MX - Messico 1
SE - Svezia 1
TR - Turchia 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
Totale 314
Città #
Dallas 22
Singapore 18
Carbonia 12
Chandler 10
Munich 10
Ashburn 7
Chicago 7
Bengaluru 6
Hefei 6
Turku 6
Rome 5
Ercolano 4
Hanoi 4
Ho Chi Minh City 4
London 4
Milan 4
Santa Clara 4
Afragola 2
Beijing 2
Brescia 2
Lawrence 2
Manaus 2
Montreal 2
New York 2
Nuremberg 2
Porto Alegre 2
Princeton 2
Reggio Calabria 2
San Nicola Manfredi 2
São Paulo 2
West Lafayette 2
Alvorada 1
Baghdad 1
Bagé 1
Balıkesir 1
Beirut 1
Benevento 1
Boardman 1
Bragança Paulista 1
Brasília 1
Buffalo 1
Caicó 1
Campina Grande 1
Cape Town 1
Chaguanas 1
Charlotte 1
Chennai 1
Cleveland 1
Cosenza 1
Crestview 1
Dolores Hidalgo 1
Helsinki 1
Isidro Casanova 1
Itabira 1
Jacarezinho 1
Jaraguá do Sul 1
Johannesburg 1
King City 1
La Paz 1
Lajeado 1
Los Angeles 1
Louisville 1
Maracaibo 1
Mosul 1
Naples 1
Nasiriyah 1
Niterói 1
Norwich 1
Nova Iguaçu 1
Olomouc 1
Osasco 1
Padang 1
Palermo 1
Parma 1
Passo Fundo 1
Petrópolis 1
Ponto Belo 1
Rio de Janeiro 1
Rostov-on-Don 1
San Hilario 1
Satuba 1
St Petersburg 1
Stockholm 1
Thái Bình 1
Toronto 1
Torres 1
Ubá 1
Zipaquirá 1
Totale 218
Nome #
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 96
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 62
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 56
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 48
Clinical profile of trazodone users in a multisetting older population: data from the Italian GeroCovid Observational study 32
LNA-i-miR-221 activity in colorectal cancer: A reverse translational investigation 31
Totale 325
Categoria #
all - tutte 2.075
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.075


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225 0 0 0 0 0 0 2 0 1 1 1 0
2022/202327 4 4 0 2 3 2 0 0 8 1 2 1
2023/202438 15 2 6 1 2 6 0 0 0 0 3 3
2024/2025142 7 3 0 5 11 23 7 3 7 4 34 38
2025/2026113 15 17 33 22 21 5 0 0 0 0 0 0
Totale 325